Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Vanda Pharmaceuticals Inc. (VNDA : NSDQ)

• Company Description    Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. Number of Employees: 203

• Price / Volume Information    Yesterday's Closing Price: $8.82 Daily Weekly Monthly 20 Day Moving Average: 2,695,086 shares Shares Outstanding: 59.10 (millions) Market Capitalization: $521.23 (millions) Beta: 0.60 52 Week High: $9.60 52 Week Low: $3.81 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 69.61% 69.90% 12 Week 61.83% 59.22% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2200 PENNSYLVANIA AVENUE NW SUITE 300E - WASHINGTON,DC 20037 USA ph: 202-734-3400 fax: 202-296-1450 pr@vandapharma.com http://www.vandapharma.com

• General Corporate Information    Officers Mihael H. Polymeropoulos - Chief Executive Officer; Chairman and President Kevin Moran - Chief Financial Officer Richard W. Dugan - Director Anne Sempowski Ward - Director Phaedra Chrousos - Director Peer Information Vanda Pharmaceuticals Inc. (CORR.) Vanda Pharmaceuticals Inc. (RSPI) Vanda Pharmaceuticals Inc. (CGXP) Vanda Pharmaceuticals Inc. (BGEN) Vanda Pharmaceuticals Inc. (GTBP) Vanda Pharmaceuticals Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 921659108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/12/26 Share - Related Items Shares Outstanding: 59.10 Most Recent Split Date: (:1) Beta: 0.60 Market Capitalization: $521.23 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.26 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.51 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.12 Price/Cash Flow: - Price / Sales: 2.46 EPS Growth vs. Year Ago Period: -322.22% vs. Previous Quarter: 17.39% Sales Growth vs. Year Ago Period: 18.06% vs. Previous Quarter: 6.97% ROE 12/31/25 - - 09/30/25 - -16.82 06/30/25 - -12.89 ROA 12/31/25 - - 09/30/25 - -13.40 06/30/25 - -10.47 Current Ratio 12/31/25 - - 09/30/25 - 3.12 06/30/25 - 3.25 Quick Ratio 12/31/25 - - 09/30/25 - 3.10 06/30/25 - 3.23 Operating Margin 12/31/25 - - 09/30/25 - -39.70 06/30/25 - -32.90 Net Margin 12/31/25 - - 09/30/25 - -39.70 06/30/25 - -32.90 Pre-Tax Margin 12/31/25 - - 09/30/25 - -50.52 06/30/25 - -41.77 Book Value 12/31/25 - - 09/30/25 - 7.89 06/30/25 - 8.23 Inventory Turnover 12/31/25 - - 09/30/25 - 6.01 06/30/25 - 6.13 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.01 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.60 06/30/25 - 0.00

Powered by Zacks Investment Research ©